Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.

Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against ...

I'll be honest about something upfront: I didn't finish the original Assassin's Creed IV: Black Flag back in 2013, nor did I ...